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ABSTRACT
HLA-DR1 transgenic (DR1 Tg) mice provide a model for evaluating
the breadth and specificity of CD4 T cell responses that may develop in
humans following influenza infection or vaccination. Recent studies
identified a tremendously broad HLA-DR1-restricted CD4 T cell responses
in

DR1

Tg

mice

infected

intranasally

with

influenza

A/New

Caledonia/20/99 (NC). In this study, our goals were to characterize B cell
responses after NC infection in DR1 Tg mice and establish the correlation
between B cell responses and CD4 T cell responses in this system.
Influenza-specific B cell responses following virus administration were
analyzed in DR1 Tg mice and in the genetically matched H-2b strain
C57BL/10J (B10).
Following intranasal (i.n.) NC infection, B cell responses in B10 mice
featured strong IgG2b and IgG2c production and were typical of previously
described B cell responses to a variety of mouse-adapted influenza strains.
In contrast, B cell responses in DR1 Tg mice followed delayed kinetics
and were strongly skewed to IgG1 production, suggesting the Th2
polarization of CD4 T cell responses. The different antibody isotype profile
in DR1 Tg mice compared to B10 mice was evident in antibody secreting
cells (ASCs) frequencies and in circulating Abs levels. Surprisingly,
although DR1 Tg mice had lower influenza-specific Abs levels, they
exhibited higher neutralizing Abs titers early in the response.
B cell responses following intranasal infection of influenza A/Puerto
Rico/8/1934 (PR8) or intramuscular vaccination of inactivated NC in DR1
Tg mice were different from the observed IgG1 bias after i.n. NC infection.
After i.n. PR8 infection, B cell responses were characterized by
predominant IgM/IgG3 production, which was similar in DR1 Tg mice and
iii

B10

mice.

Additionally,

following

intramuscular

administration

of

inactivated NC, B cell responses were skewed towards IgG2c production
in both DR1 Tg mice and B10 mice, suggesting the Th1 polarization of
CD4 T cell responses. A mechanistic understanding of IgG1/Th2 biased B
cell responses and better neutralizing Abs production in DR1 Tg mice
following i.n. NC infection may have implications for the optimal control of
influenza infection.
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CHAPTER 1
INTRODUCTION
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I. Overview of influenza viruses
The influenza virus is one of the most important human respiratory
pathogens and attacks the host respiratory tract mucosa, causing
seasonal outbreaks, endemic infections and periodic pandemics [1].
Influenza viruses are enveloped viruses belonging to the family
Orthomyxoviridae and contain a negative, segmented, single-stranded
RNA genome [2]. Based on antigenic differences of core proteins,
nucleoprotein (NP) and matrix protein (M), influenza viruses are divided
into types A, B and C [3]. Based on antigenic differences of two surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), type A viruses
are further subdivided into subtypes [3]. Currently, 16 HA (H1-H16) and 9
NA (N1-N9) subtypes have been identified in influenza A viruses [4].
Influenza A viruses have been isolated from various animals,
including birds, pigs, horses, humans and sea mammals, whereas type B
and C influenza viruses are predominantly found in humans [5]. Influenza
A and B viruses cause annual epidemics or local outbreaks of influenza in
humans [1]. All different subtypes of influenza A can be found in avian
hosts, and therefore aquatic birds are thought to be the natural reservoir of
influenza A viruses [6]. However, since the last century, only H1N1, H2N2,
and H3N2 subtypes have been associated with widespread epidemics in
humans [2]. Although a number of avian influenza viruses (H5N1, H9N2,
and H7N7) have crossed the species barrier and directly infected humans,
they still have not developed the capacity for efficient human-to-human
transmission [3].

Genetics of the influenza A virus
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The genome of influenza A viruses (Fig. 1) contains eight singlestranded, negative-sense RNA segments and codes for at least 10
proteins in vivo by using different reading frames and alternative RNA
splicing [3]. The virus particle has a lipid envelope that is derived from the
host cell during budding through the cell membrane [5]. Three proteins are
embedded in the lipid bilayer: the rod-shaped HA, the mushroom-shaped
NA, and the matrix protein 2 (M2) [3]. The matrix protein 1 (M1) is the
most abundant protein in the virus particle and locates right below the lipid
bilayer [7, 8]. Genomic RNA segments are encapsulated with the
nucleoprotein (NP) and are associated with three RNA polymerase
proteins (PB1, PB2, PA) to form ribonucleoprotein (RNP) complex [3, 9].
The virus also encodes nonstructural proteins NS1 and NS2. NS1
counteracts the type I interferon antiviral program of host cells by
sequestering viral RNAs from intracellular receptors; NS2, also referred to
as the nuclear export protein (NEP), is involved in the process of nuclear
export of RNPs and viral assembly [10].

Figure 1. Structure of the influenza A virus [7]
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Two major surface glycoproteins, HA and NA, are the most important
targets of neutralizing Abs during influenza infection [1, 11]. HA is
responsible for the binding of viruses to sialic acid-containing receptors
and the membrane fusion between the virus and the host, resulting in the
release of viral RNPs into host cells [8]. NA cleaves sialic acid residues of
cellular receptors and releases new viruses [3].

Pathogenesis of the influenza A virus
Influenza

is

an

acute

and

contagious

respiratory

disease,

characterized by the sudden onset of systemic and respiratory symptoms
including fever, headache, cough, sore throat and rhinitis etc. [3]. All
influenza A subtypes are carried in the gastrointestinal tract of wild birds
asymptomatically, but may cause diseases in domestic birds and
mammals [12].
Influenza viruses are constantly undergoing antigenic changes to
escape the host adaptive immunity in two ways: antigenic shift and
antigenic drift [3]. Due to the segmented viral genome, influenza viruses
can easily reassort segments from different strains in a doubly infected
host [3]. The reassortment will result in the emergence of a new subtype
with novel antigenic properties, referred to as antigenic shift [3]. Antigenic
shift can also occur when an avian strain is directly transmitted to humans
without reassortment [13]. Antigenic shift happens at infrequent and
unpredictable intervals. Since a large proportion of human populations
have little or no immunity to the new subtype and antibodies against the
previously circulating strain do not cross-react with it, the new subtype
possesses the potential to cause a global pandemic [3, 8]. Viruses
causing the pandemics of 1957 and 1968 were derived from the
reassortment of avian and human viruses [14, 15].
4

Antigenic drift results from the continuous accumulation of minor
genetic mutations in all gene segments, mostly in surface glycoproteins
HA and NA [3]. Viral RNA-dependent RNA polymerase complex lacks
proofreading abilities, resulting in high rates of point mutations (~ 1/104
base per replication cycle) during genome replication [16]. Variant strains
of the same subtype contribute to annual epidemics or local outbreaks of
influenza.
The binding specificity of HA for host cells is thought to be a major
determinant of whether an influenza strain can infect a host [7]. An
important difference between avian and human viruses is their binding
preferences for specific sialic acid linkages on host cells [2]. Most avian
influenza viruses preferentially bind to α-2,3 sialic acid linkages, whereas
human strains preferentially bind to α-2,6 sialic acid linkages [17, 18].
Upper respiratory tract epithelial cells of birds and human preferentially
express virus receptors with α-2,3 sialic acid linkages and α-2,6 sialic acid
linkages, respectively, whereas respiratory epithelial cells of pigs express
receptors with both α-2,3 and α-2,6 sialic acid linkages [19].
The receptor binding specificity and expression pattern has led to the
hypothesis that pigs serve as a “mixing vessel” which facilitates antigenic
shift [15, 19]. When pigs are infected with human and avian viruses
simultaneously, reassortment may occur to give rise to a new pandemic
strain with efficient human-to-human transmission capacity [7]. The
receptor binding specificity and expression pattern also accounts for the
usual restriction of infection by avian strains to birds and pigs but not
humans [2]. However, research showed that a human virus A/New
Caledonia/20/99 was able to replicate effectively in mice lacking α-2,6
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sialic acid linkages, indicating that this restriction was not totally absolute
[20].
HA is synthesized as an HA0 precursor, which needs to be cleaved
into two subunits HA1 and HA2 by host proteases at a conserved arginine
residue [7, 9]. HA of highly pathogenic avian influenza (HPAI) has a series
of basic amino acids at the cleavage site enabling HA to be cleaved by
ubiquitous proteases, which facilitates systemic infection and spread of
the virus [21]. Therefore, HA cleavability is considered as another major
determinant of virus pathogenicity.
Other gene segments can also contribute to the pathogenicity of
influenza viruses. It is still not clear what resulted in the extreme virulence
of the extinguished 1918 pandemic strain. Research based on the
successful reconstruction of this strain showed that HA, NA, and PB1
genes were responsible for the high replication efficiency of the
reconstructed strain observed in mouse and human airway cells [22]. PB1
gene probably played a crucial role in the 1918 virus virulence [22]. PB2
gene appeared to contribute to the efficient transmission of viruses by
allowing enhanced replication at a lower temperature in the airway of
mammals [23].

Epidemiology
Influenza epidemics usually occur between November and March in
the northern hemisphere and between April and September in the
southern hemisphere [2]. Influenza is responsible for over 100,000
hospitalizations and around 20,000 deaths annually in the US [24, 25].
During a pandemic, which usually happens every several decades, the
morbidity and mortality increase dramatically.
6

There were three influenza pandemics in the last century [26]. The
1918-1919 Spanish influenza was caused by a H1N1 strain and killed
more that 40 million people [27]. Almost 50% of deaths occurred in an
unusually young age group, 20-40-year-olds [28]. A new influenza H2N2
virus was responsible for the 1957 Asian influenza pandemic and was first
isolated in Japan in May 1957 [2]. A H3N2 strain caused the third
pandemic and was isolated at Hong Kong in 1968 [2]. This strain
contained avian HA (H3) and PB1 segments, and shared other segments
with the previously circulating H2N2 virus [5].
In late March and early April 2009, an outbreak of H1N1 influenza A
virus infection was detected in Mexico, followed by many other countries
including the US [29]. The pandemic (H1N1) 2009 influenza A virus is a
new reassortant comprising two swine strains, one human strain and one
avian strain [26]. Recent data from numerous outbreak sites show that the
pandemic (H1N1) 2009 virus is currently the dominant strain circulating in
most parts of the world [30].

II. The immune response to influenza viruses
The respiratory tract mucosa is not only the site of influenza infection
but also the site of defense against influenza infection in the host [1]. The
kinetics study of the influenza A virus showed that infected epithelial cells
started to produce viruses 6 hours after infection [31]. The virus titer in the
lung usually peaks 2-3 days post-infection, and becomes undetectable
around 10 days post-infection [32]. However, the host adaptive immune
response needs about one week to develop [32]. Therefore, in order to
control virus infection or recover from influenza, both innate and adaptive
immune responses should be induced [1].
7

Innate immunity to influenza viruses
The innate immune response triggered by virus infection functions as
the first line of defense to restrict viral spread. The innate system consists
of effector cells (such as epithelial cells, NK cells, macrophages, and
plasmacytoid dendritic cells), cytokines and chemokines (including IFNs,
TNF-α, IL-1, IL-6, IL-12, MIP-1, IP-10), and complements [1, 33]. The
recognition of viral RNAs by TLRs induces the production of cytokines and
chemokines by infected lung epithelial cells and macrophages [34, 35].
The cytokines and chemokines then contribute to attracting monocytes
and T cells from peripheral blood into the site of infection within the first 3
days after infection [34].
Type I IFNs, which are produced by infected epithelial cells,
macrophages, and plasmacytoid dendritic cells, are important components
of the innate immune response due to their direct antiviral effects [7]. The
IFN-α/β response starts within 12 hours after infection and lasts for
several days [36]. Type I IFNs influence CD4 differentiation resulting in
the development of Th1 effector cells that in turn produce high levels of
IFN-γ and IL-2 [37].

Adaptive immunity to influenza viruses
After influenza viruses successfully escape the innate immune
response and establish intracellular infection, the adaptive immune system
will play a key role in the host defense by detecting and eliminating
infected cells [38]. The adaptive immunity is comprised of cell-mediated
immune system and humoral immune system.
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The cell-mediated immune system, consisting of CD4 T cells and
CD8 T cells, is essential for virus clearance during influenza infection [3].
CD8 T cells, also called cytotoxic lymphocytes (CTLs), recognize an
antigenic peptide-MHC class I complex through TCRs and become
activated [1]. Activated CTLs not only directly lyse infected cells, but also
secret pro-inflammatory and anti-viral cytokines, such as IFNs [39]. CD4 T
cells recognize antigenic peptide-MHC class II complex on APCs and then
differentiate into different subtypes, such as Th1, Th2, Treg, and Th17 [40].
Th1 cells secrete IFN-γ and IL-2, and provide help for CD8 T cells
proliferation and IgG2a/IgG2c production by antibody secreting cells
(ASCs); Th2 cells secrete IL-4 and IL-5, and help IgA, IgG1 and IgE
production by ASCs [34].
The humoral immune system relies on the production of antibodies
by B cells to protect against influenza. Virus-specific Abs against HA and
NA are thought to be the most protective [32]. Anti-HA Abs neutralize the
infectivity of viruses, and anti-NA Abs reduce the release of viruses from
infected cells [41]. Abs to the conserved protein M2 are cross-protective
among different subtypes, while Abs to the conserved NP and M1 fail to
contribute to protection [42, 43]. The secretory IgA (sIgA) produced locally
at mucosal sites is the major neutralizing antibody to prevent virus
entrance especially at the upper respiratory tract [3].
Long-lived plasma cells and memory B cells also contribute to the
protective immune response [44]. They are able to induce rapid recall
responses and produce high-affinity antibodies to neutralize viruses, which
are important to control the spread of viruses during the early stage of
infection [45]. Long-lived plasma cells reside in the bone marrow after
infection and constitute the main source of circulating antibodies in serum
as well as antibodies at mucosa sites [46]. Memory B cells usually
9

circulate and disperse to secondary lymphoid organs throughout the body
[47]. An analysis of memory B cells induced by influenza infection
identified the lung as a non-lymphoid site where memory B cells as well as
ASCs preferentially localize [48].

III. B cell activation, proliferation and differentiation
After their generation and maturation in the bone marrow, naïve B
cells migrate to the blood and enter secondary lymphoid organs through
high endothelial venules (HEVs) in the outer T cell zone and interfollicular
regions [49, 50]. B cells then migrate to B cell follicles where they are
retained for up to 24 hours to scan for specific antigens [49]. This
migration is dependent on the expression of CXCR5 by B cells and its
ligand CXCL13 by follicular stromal cells [51]. Inside follicles B cells are
highly motile in a “random walk” fashion and search for antigens [52].
So how do antigens get into lymph nodes from outside and where do
B cells encounter antigens? Antigens of low molecular weight can freely
diffuse into B cell follicles via pores on the floor of subcapsular sinus (SCS)
[53]. Antigens can also travel through conduits into B cell follicles [54].
Dendritic cells (DCs) use Fc receptor FcγRIIB to non-degradatively uptake
antigens and then migrate to the T cell zone [55]. Therefore newly arriving
B cells via HEVs have the chance to encounter antigen-bearing DCs
during their migration to B cell follicles [50].
Recently, the use of two-photon microscopy identified the SCS
macrophage as another important antigen encounter site within the first
few hours of the immune response [56-58]. When antigens entered LNs
via lymph flow, SCS macrophages captured immune complexes (ICs),
viruses or virus-like particles, and then presented intact antigens to
10

follicular B cells [59]. Noncognate B cells were observed to capture ICs
from SCS macrophages by complement receptor 1 and 2 (CR1/2) and
deliver these ICs to follicular dendritic cells (FDCs) within follicles [58].
FDCs as specialized Ag-trapping cells within follicles can retain ICs on
their surface and present intact antigens to B cells [59].
After encountering antigens in B cell follicles, B cells recognize and
bind to antigens by the B cell receptor (BCR) [60]. The BCR consists of
membrane immunoglobulin (mIg) associated with Igα-Igβ heterodimers
[61]. Antigens are internalized through binding to BCRs, processed within
specific endosomal compartments, and finally presented in complexes
with MHC class II molecules [62]. Antigen-engaged B cells then migrate to
the B-T boundary where activated T cells also relocate [50]. B cells can be
retained there to allow for encountering CD4 helper T cells and forming
stable cognate T-B interactions to get essential help signals for further
differentiation. Then activated B cells can undergo one of two
differentiation pathways: the extrafollicular pathway or the germinal center
pathway [63, 64].
In the extrafollicular pathway, activated B cells migrate to sites
without T cells and differentiate into plasmablasts [65, 66]. After ~3 days
these plasmablasts further differentiate into short-lived plasma cells to
secrete antibodies with low affinities [67]. In the germinal center reaction,
activated B cells migrate to the center of B cell follicles and proliferate
within the FDCs network, resulting in the formation of the germinal center
(GC) [64]. The GC is the main site of supporting the antibody affinity
maturation and the generation of memory B cells. The dark zone and the
light zone are termed in the GC on the basis of their histological
appearances [68].
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According to a classic model of antibody affinity maturation, B cells in
the dark zone, called “centroblasts”, undergo extensive proliferation and
somatic hypermutation [68]. Centroblasts then migrate to the light zone
and differentiate into smaller “centrocytes” [68]. Centrocytes undergo the
selection for high affinity BCRs with the help of FDCs and Follicular helper
T (Tfh) cells [68]. FDCs are capable of capturing large amount of intact
antigens in the form of ICs [69]. The follicular helper T cell is a subset of
activated CD4 T cells [70]. By competing for binding to antigens displayed
on the surface of FDCs, B cells with high affinity BCRs are selected [68].
Selected centrocytes then present antigens to Tfh cells through MHC II
complex and compete for help signals [70]. B cells that survive and
contain high affinity BCRs exit the GC and become high affinity plasma
cells or memory B cells [68].

IV. CD4 T cell responses and MHC class II-restricted
epitopes study
Naïve CD4 T cells are activated by professional APCs (such as
dendritic cells) in the T cell zone of secondary lymphoid organs. Activated
T cells are induced to differentiate into Th1 cells by IFN-γ and IL-12, or into
Th2 cells by IL-4 [40]. Activated CD4 T cells up-regulate the CD40L
expression and secret different cytokines, such as IFN-γ and IL-2 from Th1
cells and IL-4, IL-5 and IL-10 from Th2 cells, to provide help for B cell
proliferation and immunoglobulin isotypes switching [71, 72].
APCs process exogenous antigens into small fragments and finally
present antigenic peptides in the context of MHC (major histocompatibility
complex) class II molecules [73]. MHC molecules are classified into class I,
II, III groups and are different in humans and mice called HLA and H-2,
respectively [74]. MHC class I-restricted epitopes of influenza viruses are
12

better characterized than MHC class II-restricted epitopes of influenza
viruses in murine models [75].
According to most of published literatures regarding CD4 T cell
specific epitopes of influenza viruses, epitopes with high frequencies were
derived from HA and NP [76]. Based on different murine models and virus
isolates, the source and distribution of CD4 T cell epitopes would vary. In
C57BL/6 mice after infection of influenza A/HK-x31, a large number of
MHC class II-restricted epitopes (around 20-30) were unevenly distributed
within limited proteins, with the majority deriving from NP and HA [75].
However, in BALB/c mice, multiple epitopes were also identified in NA of
x31 viruses [75].
According to the study involving HLA-DR1 transgenic (DR1 Tg) mice
and a human influenza isolate A/New Caledonia/20/99 (NC), the repertoire
of HA-specific CD4 T cells after primary NC infection was very diverse [77];
More than 30 epitopes were identified within the entire HA protein,
including epitopes genetically conserved across H1, H2, and H5 influenza
viruses [77]. Besides HA, CD4 T cell specific epitopes were also identified
in NA, NP and NS [77].
Different hosts express distinct MHC class II molecules, resulting in
different repertoires of CD4 T cells. The immune response in DR1 Tg mice
containing a human MHC class II molecule may accurately reflect the
immune response in humans after natural influenza virus infection. In
addition to the CD4 T cell response, the B cell response is another
important component of the adaptive immune response against influenza
viruses. However, the B cell response in DR1 Tg mice after primary NC
infection has not been investigated. In this study, our goals were to
characterize B cell responses after NC infection in DR1 Tg mice and
13

establish the correlation of B cell responses with CD4 T cell responses in
the same mouse model system.
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CHAPTER 2
MATERIALS AND METHODS
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I.

Mice
HLA-DR1 transgenic mice were got from Dr. Zaller (Merck) through
Taconic laboratories and were housed and propagated under
specific pathogen-free conditions at the animal center of the
University of Tennessee. Mice were immunized at 2-3 months of
age and were thereafter kept in BSL-2 containment.
C57BL/10J mice purchased from The Jackson Laboratory were
housed under specific pathogen-free conditions until immunization
and thereafter in BSL-2 containment. Female mice were used in all
experiments and were infected at 8-12 weeks of age.
The Animal Care and Use Committee of the University of
Tennessee approved all animal procedures.

II.

Viruses
Influenza virus A/New Caledonia/20/99 (NC) grown and titrated in
the allantoic cavity of embryonated hen’s eggs was obtained from
Dr. Richard Webby (St. Jude Children’s Research Hospital,
Memphis, TN). Influenza virus A/Puerto Rico/8/1934 (PR8) was
grown and titrated in the allantoic cavity of embryonated hen’s eggs.
Clone G2.4 of MHV-68 was originally obtained from Dr. A. A. Nash
(Edinburgh, U.K.), and virus stocks were grown in owl monkey
kidney cells and titrated on NIH-3T3 cells.
Viruses were inactivated by treatment with ß-propiolactone. Viral
protein concentrations were measured using the Bio-Rad protein
16

assay kit (Bio-Rad, Hercules, CA). All virus preparations were
stored at -80 °C

III.

Immunization of mice
Mice were anesthetized with Avertin (2,2,2-tribromoethanol) given
intraperitoneally before all immunizations.
For intranasal (i.n.) infection, mice were infected with 20,00040,000 50% egg infectious doses (EID50) of NC, or 25 EID50 of PR8,
or 104 PFU of MHV-68 (30 µl in PBS).
For intramuscular (i.m.) immunization, a total dose of 20 µg of
inactivated NC was given in two injections, each of 10 µg (50 µl in
PBS), into the tibialis anterior muscle of each leg. A plastic sleeve
over the needle was used to control the depth of injections.

IV.

Tissue dissection and treatment
Anesthetized mice were exsanguinated via the retro-orbital plexus
before organs were collected. Organs were processed to generate
single-cell suspensions in IMDM media (Invitrogen, Carlsbad, CA)
containing L- glutamine (2 mM), sodium pyruvate (1 mM), penicillin
(100 IU/ml), streptomycin (100 µg/ml), gentamicin (10 µg/ml), and 5
× 10-5 M ß-mercaptoethanol (designated B cell medium), and
supplemented with 10% FBS. Lymph nodes (CLN, MLN, PLN, IliLN,
IngLN) and spleens were collected and gently disrupted between
frosted ends of microscope slides. Bone marrow (BM) cell
suspensions were obtained by flushing femurs and tibiae. Red
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blood cells (RBCs) were removed from spleen and BM preparations
by ammonium chloride lysis. Lungs were perfused with PBS prior to
collection, and then were finely minced and incubated for 1 hour at
37 °C in BCM containing 10% FBS and 4 mg/ml collagenase type
II (Worthington, Lakewood, NJ). Cells pelleted from the lung digest
were resuspended in 40% isotonic Percoll and layered over 75%
isotonic Percoll. After centrifugation at 600 × g for 20 min at 25 °C,
cells at the interface were collected and washed. Lungs to be
titrated for infectious viruses were homogenized in 1 ml HBSs
containing antibiotics and 0.1% BSA. Homogenates were clarified
by centrifugation, and supernatants were collected and stored at 80°C. Sera were collected from clotted blood and stored at -80 °C
for antibody analysis.

V.

ELISPOT assay
A preparation of concentrated viral particles was disrupted for 10
min at room temperature in a 1 in 10 dilution of disruption buffer
(0.5% Triton X-100, 0.6 M KCl, and 0.05 M Tris-HCl, pH7.5) in PBS,
further diluted in PBS, and plated at 1 µg/well in nitrocellulosebottomed 96-well MultiScreen HA filtration plates (Millipore, Bedford,
MA). After overnight incubation at 4°C, plates were washed with
PBS, and then were blocked with BCM containing 10% FBS for 1
hour. Plates were emptied by flicking, and were washed with PBS.
Single-cell suspensions were then added to plates in a volume of
100 µl/well. After incubation for 3-4 hours at 37°C in a humidified
atmosphere containing 5% CO2, plates were thoroughly washed
with PBS alone and PBS containing 0.1% Tween 20.
Phosphatase-conjugated

Goat

Anti-Mouse

IgGs,

Alkaline

IgM,

IgA

(Southern Biotechnology, Birmingham, AL) diluted to 2 µg/ml in
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PBS containing 5% BSA were added to plates in a volume of 100
µl/well, and plates were then incubated overnight at 4°C. Plates
were washed thoroughly with PBS alone and PBS containing 0.1%
Tween 20, including washing the underside of the nitrocellulose
filter. Spots were developed at room temperature by adding 100
µl/well of 1 mg/ml of 5-bromo-4-chloro-3-indolylphosphate (Sigma,
St. Louis, MO) in diethanolamine buffer (10% diethanolamine, 0.1
M NaCl, 5 mM MgCl2, and 0.1 M Tris-HCl, pH 9.5). After optimal
spots development, plates were washed with PBS and dried at
room temperature. Spots representing individual antibody secreting
cell (ASC) were counted using an Olympus SZX9 stereozoom
microscope.

VI.

ELISA
A preparation of concentrated viral particles was disrupted for 10
min at room temperature in a 1 in 10 dilution of disruption buffer
(0.5% Triton X-100, 0.6 M KCl, and 0.05 M Tris-HCl, pH 7.5) in
PBS, further diluted in PBS, and plated at 0.5 µg/well in 96-well flat
bottom immuno plates (Nalge Nunc International, Rochester, NY) in
a volume of 50 µl/well. After overnight incubation at 4°C, plates
were washed with PBS containing 0.05% Tween 20, and were
blocked with PBS containing 3% BSA for at least 90 min in a
volume of 150 µl/well at room temperature. Plates were emptied by
flicking, and were washed with PBS containing 0.05% Tween 20.
Serum samples were serially 3-fold diluted in PBS containing 0.5%
BSA and 0.05% Tween 20, and were added to plates in a volume
of 50 µl/well. Plates were incubated for 3-4 hours at room
temperature or overnight at 4°C, and then were washed with PBS
containing 0.05% Tween 20. Alkaline Phosphatase-conjugated
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Goat Anti-Mouse Abs with specificities for IgGs, IgA, IgM or Ig (H+L)
(Southern

Biotechnology,

Birmingham,

AL)

diluted

in

PBS

containing 1% BSA were added in a volume of 100 µl/well, and
plates were incubated for 2-4 hours at room temperature or
overnight at 4°C. After plates were washed with PBS containing
0.05% Tween 20, color was developed by adding 5 mg/15ml of pnitrophenyl phosphate substrate (Sigma, St. Louis, MO) in
diethanolamine buffer (10% diethanolamine, 0.1 M NaCl, 5 mM
MgCl2, and 0.1 M Tris-HCl, pH 9.5) in a volume of 100 µl/well at
room temperature for 20-30 min. Absorbance was measured at 405
nm in the Synergy 2 multi-Detection Microplate Reader using Gen5
software (Biotek). Titers of virus-specific Abs were determined as
the reciprocal of the highest dilution giving an absorbance value
larger than 0.1 and at least two-fold higher than the absorbance of
simultaneously titrated naïve samples.

VII.

Virus titration
Viral titers in lung homogenates were determined by 50% tissue
culture infection dose (TCID50) using Madin-Darby Canine Kidney
(MDCK) cells grown in MEM medium (Invitrogen, Carlsbad, CA)
containing L- glutamine (2 mM), penicillin (100 IU/ml), streptomycin
(100 µg/ml), gentamicin (10 µg/ml), and supplemented with 5%
FBS. Confluent cell monolayer in a 96-well tissue culture plate was
washed twice with FBS-free MEM medium containing 0.3% BSA
immediately before the transfer of viral inocula. Serial 10-fold
dilutions of lung homogenates were prepared on a 96-well round
bottom polypropylene plate (Corning Incorporated, Corning, NY).
Add 225 µl of MEM containing L- glutamine (2 mM), penicillin (100
IU/ml), streptomycin (100 µg/ml), gentamicin (10 µg/ml), 0.3% BSA
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and 2 µg/ml L-(tosylamido-2-phenyl) ethyl chloromethylketone
(TPCK) -treated Trypsin (Worthington, Lakewood, NJ) (designated
VGM) to every well. Add 25 µl of lung homogenates to the first well
of each row. Mix and transfer 25 µl to successive wells to generate
10-fold dilutions. Transfer 200 µl of lung homogenate dilutions to
corresponding wells of the washed MDCK cells plate. After 2-3
days incubation at 37°C in a humidified atmosphere containing 5%
CO2, observe the plate under an inverted microscope for viral CPE,
and draw 50 µl/well of supernatants to perform HA assay. Calculate
the TCID50 by the Reed-Muench method.

VIII.

Hemagglutination assay (HA)
Orient a 96-well round bottom polystyrene assay plate (Corning
Incorporated, Corning, NY) so that samples will be diluted 12 wells
across. Number the row on each plate to identify different samples.
Add 50 µl PBS to every well on the plate. Add virus suspensions or
cell culture supernatants to the first well in each row in a volume of
50 µl. Note that this will result in a 1:2 dilution of the test sample in
the first well. A positive control and a negative control (such as PBS
only) must be included. Mix the content of the first well by pipetting
up and down 10 times and transfer 50 µl to successive wells to
make 2-fold dilutions of the sample across the entire row. Discard
the final 50 µl after the last row. At this point every well should have
a volume of 50 µl.

Add 50 µl of 0.5% chicken red blood cells

(RBCs) suspension (Fitzgerald, Concord, MA) to every well. Mix the
plate by using a mechanical vibrator or by taping the plate gently.
Incubate the plate at room temperature for an appropriate time (3060 min) by checking negative control wells for complete settling of
RBCs.
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Results of the HA assay should be interpreted when RBCs in
negative control wells had settled down to form solid buttons at the
bottom of wells (hemagglutination-negative). When the plate was
tilted at approximate 45-degree, RBCs in negative control wells
would stream down in a “tear-drop” fashion. Samples that were
hemagglutination-negative should also form solid buttons at the
bottom of wells and slide down at the same rate as negative
controls. Samples showing complete hemagglutination in one or
more wells were considered hemagglutination-positive. Incomplete
hemagglutination was observed as buttons that did not slide, had
fuzzy margins, or formed a doughnut-shaped ring at the bottom of
wells. The endpoint of a sample was the highest dilution causing
complete hemagglutination. The endpoint dilution was considered
containing one hemagglutination unit (HAU), and the number of
HAUs/50 µl was the reciprocal of the highest dilution.

IX.

Hemagglutination inhibition assay (HAI)
a. Treatment of sera
Sera against influenza viruses prepared in most animals
(ferret, rabbit, mouse) must be treated with receptor
destroying

enzyme

(RDE)

to

eliminate

nonspecific

hemagglutination inhibitors. RDE (II) “SEIKEN” (Denka
Seiken CO. LTD, Tokyo, Japan) was completely dissolved in
20 ml of sterile physiological saline, 0.85% NaCl. This
solution should be used immediately or be aliquot and stored
at - 20°C or less. Under sterile condition add 3 vols of RDE
to 1 vol of sera (such as 90 µl RDE + 30 µl sera), and mix
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thoroughly. Heat the mixture in a 37°C waterbath for 18-20
hours to allow the reaction to occur. Then heat the mixture in
a 56°C waterbath for 30-60 min to inactivate remaining RDE.
Allow the mixture to cool down to room temperature. Add 6
vols of sterile physiological saline, 0.85% NaCl (such as 180
µl). The final dilution of the sera was 1:10.
b. HA titration of the control antigen
The control antigen was titrated by following the procedure
of hemagglutination assay described above. The endpoint of
a sample was the highest dilution causing complete
hemagglutination. The endpoint dilution was considered
containing one hemagglutination unit (HAU), and the number
of HAUs/50 µl was the reciprocal of the highest dilution.
Calculate the HAUs/50 µl of the control antigen.
c. Preparation of standardized antigens for HAI and “Back
titration”
Standardized antigens used for HAI should have 4 HAUs/25
µl or 8 HAUs/50 µl. Calculate the antigen dilution by dividing
the HAUs/50 µl of the control antigen by 8 in order to get 8
HAUs/50 µl of standardized antigens. Make the dilution in an
appropriate volume.
The “back titration” was performed by doing HA assay to
verify the 8 HAUs/50 µl of standardized antigens. Add 50 µl
PBS to well #1-6 on a 96-well microtiter plate. Add 50 µl
standardized antigens (8 HAUs/50 µl) to well #1. Mix and
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transfer 50 µl to successive wells to make serial 2-fold
dilutions until well #6. Discard the final 50 µl. Each well
should contain 50 µl after this step. Add 50 µl 0.5% RBCs to
each well. Mix the plate by using a mechanical vibrator or
taping gently. Incubate the plate at room temperature for 3060 min to allow RBCs to settle down at the bottom of wells.
The first three wells should be hemagglutination-positive.
Store standardized antigens at 4°C and use within the same
day.
d. Hemagglutination inhibition (HAI)
Orient a 96-well round bottom polystyrene assay plate
(Corning Incorporated, Corning, NY) so that samples will be
diluted 8 wells across. Add 25 µl PBS to wells of row B
through G (B1-G12). Add 50 µl RDE-treated samples (1:10)
to wells of row A (A1-A12) and add 25 µl the same RDEtreated samples (1:10) to wells of row H (H1-H12) as well.
Prepare serial 2-fold dilutions of treated samples by
transferring 25 µl from row A to successive wells until row G.
Discard the final 25 µl after row G. Add 25 µl standardized
antigens to wells of row A through G (A1-G12). Add 25 µl
PBS instead of standardized antigens to wells of row H (H1H12). Mix the plate by using a mechanical vibrator or taping
gently. Incubate the plate at room temperature for 1 hour.
Add 50 µl 0.5% RBCs to every well, and mix as before.
Incubate the plate at room temperature for an appropriate
time for RBCs settling. The HAI titer was the reciprocal of the
highest dilution of the sample that completely inhibited
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hemagglutination of standardized antigens. Record HAI titers
of samples.

X.

Neutralization assay
a. Preparation of test samples
Sera samples were treated with RDE as described above in
HAI assay. Orient a 96-well round bottom polypropylene
assay plate (Corning Incorporated, Corning, NY) so that
samples would be diluted 12 wells across. Add 60 µl VGM to
wells of column 2 through 12. Add 120 µl the RDE-treated
sample (1:10) to the first well of each row. Prepare serial 2fold dilutions by transferring 60 µl from the first well to
successive wells until column 12 and discard the final 60 µl.
Each well should contain 60 µl sample dilutions after this
step.
b. Addition of standardized viruses and “back titration”
Standardized viruses contain 50 TCID50/50 µl in VGM. Add 60
µl standardized viruses to each well except cell control wells.
Add 60 µl VGM instead of standardized viruses to cell control
wells.
Set up “back-titration” as follows on a separate 96-well round
bottom

polypropylene

assay

plate.

This

required

quadplications of ½ lg dilutions of standardized viruses. Add
120 µl VGM to wells of column 2 through 8, and then add 175
µl standardized viruses (50 TCID50/50 µl) to the first column.
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Generate ½ lg dilutions by transferring 55 µl from the first well
to successive wells. Discard the final 55 µl.
Plates containing sample/virus mixture, virus back-titration and
cell controls were gently agitated and incubated at 37°C in a
humidified atmosphere containing 5% CO2 for 2 hours.
c. Inoculation of MDCKs and HA assay
During the final 15-30 min of the incubation period, wash
confluent MDCK monolayers in 96-well cell culture plates
with 200 µl/well MEM containing 0.3% BSA twice. After the
completion of 2 hours incubation period of sample/virus
mixtures, empty the last wash of MDCK monolayers, and
transfer 100 µl/well sample/virus mixtures to corresponding
wells in MDCK cell plates. Change tips for each transfer.
Add 100 µl VGM to each well to bring the final volume in
MDCK plates to 200 µl/well. Incubate MDCK plates at 37°C
in a humidified atmosphere containing 5% CO2 for 2-3 days.
Then draw 50 µl/well supernatants to perform HA assay. The
neutralizing Abs titer of the sample was the reciprocal of the
highest dilution of the sample that completely prevented
virus infection of MDCK cells.

XI.

Cell surface staining and flow cytometry
Single-cell suspensions from lymph nodes (CLN, MLN) and spleens
were stained as follows. Add 1 × 106 cells to designated wells of a
96-well round bottom plate. Centrifuge the plate at 1500 rpm for 5
min at room temperature. Flick off the supernatant and vortex the
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plate to resuspend cells. Block cells with 100 µl/well Fc blocking
antibody or normal naïve mice serum diluted 1/200 or 1/100,
respectively, in PBS containing 2% FBS and 0.05% sodium azide
(FACS buffer). Cells were resuspended thoroughly and incubated
on ice for 30 min. Centrifuge the plate as before, flick off the
supernatant and vortex the plate to resuspend cells. Dilute primary
antibodies 1/200 in FACS buffer, and add to appropriate wells in a
volume of 100 µl/well and mix thoroughly. For the unstained well,
add 100 µl of PBS instead of primary antibody dilution. Wrap the
plate with foil and incubate the plate on ice for 30 min. Centrifuge
the plate as before, flick off the supernatant and resuspend cells
with 100 µl/well FACS buffer. Transfer cell suspensions to 5 ml
polystyrene round bottom tubes (Becton Dickinson, Franklin Lakes,
NJ). Add 600 µl of FACS buffer to each tube. Keep samples on ice
and covered until ready to run using FACScan and Cellquest
software. For the analysis of germinal center B cell differentiation,
cells were stained with PE-conjugated anti-Fas, PerCP-conjugated
anti-B220

(BD

Biosciences),

and

FITC-conjugated-Peanut

agglutinin (PNA) (Vector Laboratories. Inc., Burlingame, CA).

XII.

Statistics
Statistical comparisons of mean values were performed using the
unpaired T test for unpaired samples. Values of p < 0.05 were
considered statistically significant.
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CHAPTER 3
RESULTS
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I.

B cell responses in HLA-DR1 transgenic mice and C57BL/10J
mice after intranasal infection of influenza virus NC

a. Kinetic analyses of influenza-specific Abs responses to intranasal
administration of influenza virus NC
To explore influenza-specific ASCs responses in DR1 Tg
mice, naïve mice were infected with NC intranasally, and draining
lymph nodes, spleens, BMs and lungs were collected at different
time intervals post-infection. B10 mice were included to compare
with DR1 Tg mice in this experiment. The kinetics of NC-specific
ASCs responses in CLNs, MLNs, spleens, BMs and lungs were
showed in Fig. 1. On day 8 after virus infection, the virus-specific
response in the MLN of B10 mice slightly preceded responses in
the MLN of DR1 Tg mice, suggesting in DR1 Tg mice the humoral
response was delayed by some factors. In DR1 Tg mice, peak
numbers of virus-specific ASCs showed up in the CLN, MLN, and
spleen subsequent to 2 weeks after infection and progressively
decreased from 2 to 3 weeks after infection. The virus-specific
ASCs response in DR1 Tg mice was characterized by predominant
IgG1 isotype switching, which was not observed in B10 mice.
Virus-specific ASCs appeared in the BM and lung between 2 and 3
weeks after influenza infection, and IgG1 was the predominant
switched isotype in DR1 Tg mice which was consistent with ASCs
isotype profiles in draining LNs and spleens.
Levels of virus-specific Abs in sera closely reflected the
single cell analysis of the B cell response (Fig. 2). In DR1 Tg mice,
the titer of IgG1 was higher than other isotypes, and titers of all
isotypes were lower on day 8 than that of B10 mice. Regardless of
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different isotypes, the titer of virus-specific Ig in sera was lower in
DR1 Tg mice compared to B10 mice on days 8 and 10 after
infection, reflecting the delayed B cell response in DR1 Tg mice
(Fig. 3, A). The neutralization assay was conducted to measure
the titer of neutralizing Abs. DR1 Tg mice showed significantly
higher neutralizing Abs titers than B10 mice (p < 0.05) on day 14
after infection. Also DR1 Tg mice demonstrated stronger
hemagglutination inhibition activity than B10 mice on day 14 after
infection (p < 0.05). Taken together, the acute immune response
following i.n. NC infection was skewed towards the IgG1/Th2 bias
with higher neutralizing Abs titers and HAI titers in DR1 Tg mice.
The kinetics of the viral growth was determined by TCID50
using lung homogenates of infected mice (Fig. 4). At early time
points after infection there was no difference between DR1 Tg
mice and B10 mice. However, on day 10 viruses were still
detectable in DR1 Tg mice but became cleared in B10 mice,
suggesting that virus clearance was slower in DR1 Tg mice
compared to B10 mice.
b. Germinal center formation and the comparison of influenza-specific
and non-specific ASCs responses after intranasal administration of
influenza virus NC
Based on the intriguing observation of the IgG1/Th2 bias and
higher neutralizing Abs titers in DR1 Tg mice, we analyzed the GC
reaction in MLNs after i.n. NC infection in DR1 Tg mice and B10
mice. We identified by flow cytometry a distinct population of
germinal center B cells, stained with anti-B220 and anti-Fas
monoclonal antibodies and the peanut agglutinin (PNA), in both
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DR1 Tg mice and B10 mice. In DR1 Tg mice, percentages of
germinal center B cells (B220+PNAhiFashi) in MLNs were similar
with B10 mice on days 8,10, and 14, but higher than B10 mice on
day 21 (Fig. 5, A). When we compared frequencies of germinal
center B cells per lymph node, there was no difference between
two groups (Fig. 5, B). But if the frequency of germinal center B
cells were calculated per 106 lymphocytes or per 105 Blymphocytes, significant difference was showed on day 21 after
infection (Fig. 5, C-D).
Previous studies suggested that strong early polyclonal B cell
activation competed with virus-specific B cell activation and the
formation of neutralizing Abs [78]. Virus-specific and non-virusspecific ASCs frequencies in MLNs were determined after i.n. NC
infection in DR1 Tg mice and B10 mice. Since the immune
response was delayed in DR1 Tg mice, the non-specific response
also started later on day 10 post infection, with IgG1 predominating
and minimal other isotypes (Fig. 6). The non-specific ASC
response in DR1 Tg mice was weaker compared with the massive
non-specific B cell response in B10 mice at early stage. In B10
mice, total ASCs numbers peaked on day 8 post-infection and
decreased gradually on day 10 and 14. And isotype profiles of
virus-specific and total ASCs responses were similar showing
switched IgG2c bias in B10 mice (Fig. 6).

II.

B cell responses in HLA-DR1 transgenic mice and C57BL/10J
mice after intramuscular immunization of influenza virus NC
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Puzzled by the IgG1/Th2 bias in DR1 Tg mice after i.n. NC
infection, we wondered whether it was a characteristic of immune
responses of DR1 Tg mice. We immunized DR1 Tg mice and B10
mice with inactivated NC intramuscularly and collected draining
LNs and spleens to determine virus-specific ASCs frequencies on
days 8 and 11 post immunization. Isotype profiles were strikingly
similar between DR1 Tg mice and B10 mice, characterized by IgM
predominance in the IngLN, IliLN, and spleen on day 8 and
predominant IgG2c isotype switching on day 11 (Fig. 7). In DR1 Tg
mice the observed predominance of switched IgG1 after i.n. NC
infection was replaced by the IgG2c bias after i.m. administration.

III. B cell responses in HLA-DR1 transgenic mice and C57BL/10J
mice after intranasal infection of influenza virus PR8

Since the i.m. vaccination induced a different isotype profile
of B cell responses in DR1 Tg mice, we tested a different influenza
virus isolate to see whether the immune response profile could be
different. In this experiment, mice were infected with PR8 (H1N1)
intranasally. In contrast to i.n. NC infection, PR8 infection induced
earlier and stronger B cell responses in DR1 Tg mice, with
massive IgM production starting on day 6 and peaking on day 8 (~
20-fold of that of NC infection). Then the early peak of virusspecific IgM ASCs gave way to increased numbers of cells
producing IgG isotypes, particularly IgG3 (Fig. 8, B). Compared
with i.n. NC infection, PR8 infection obviously did not modify the
isotype profile of B cell responses in B10 mice (Fig. 8, A), showing
the same IgG2c predominance. Serum levels of virus-specific Abs
also reflected the single cell analysis of B cell responses (Fig. 9).
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And DR1 Tg mice showed higher neutralizing Abs titers than B10
mice on day 10 after PR8 infection (Fig. 10, A).
Influenza virus PR8 is a mouse-adapted strain, while NC has
not been adapted to grow in mice. So we wondered whether the
virus replication was different between the two strains. The viral
load in the lung after i.n. PR8 infection was measured by TCID50
using lung homogenates. There was no significant difference on
viral titers between DR1 Tg mice and B10 mice on days 6, 8, and
10 after PR8 infection (Fig. 10, B). And when we compared the
viral titer between i.n. NC infection and i.n. PR8 infection on day 8
in DR1 Tg mice and B10 mice, respectively, no difference was
observed (data not shown). However, because the infection dose
of NC was ~ 400 fold of PR8, it was obvious that PR8 replicated
better than NC in mice. Therefore, although viral titers in the lung
were similar on day 8 after NC and PR8 infection, the better PR8
virus replication in the lung may induce different cytokines
production and resulted in different B cell immune responses.

IV. B cell responses in HLA-DR1 transgenic mice and C57BL/10J
mice co-infected with NC and MHV-68 viruses intranasally

Previous studies showed i.n. MHV-68 infection mainly induced
the IgG2a/IgG2b production with a low level of IgG1 production [79].
So we were interested in whether the Th2 biased B cell response in
DR1 Tg mice following i.n. NC infection could be altered by a coinfection with MHV-68, which is a Th1 biased virus. In this
experiment, co-infected mice were sampled on days 8 and 10 after
co-infection and MLNs were collected to conduct ELISPOT assay
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to enumerate NC-specific and MHV-68-specific ASCs, respectively.
In both DR1 Tg mice and B10 mice, MHV-68-specific IgM ASCs
peaked on day 8 and was followed by increased IgGs isotypes
switching, especially the IgG2c (Fig. 11, B and D). The kinetics and
isotype profiles of NC-specific B cell responses were similar in coinfected DR1 Tg mice and B10 mice, demonstrating a IgG2c biased
immune response. However, the co-infection induced different NCspecific ASCs responses in DR1 Tg mice compared with i.n. NC
infection. The NC-specific ASCs response was changed to Th1
bias in co-infected DR1 Tg mice, with IgG2c predominating (Fig. 11,
A and C), meanwhile the i.n. NC infected DR1 Tg mice still
displayed Th2 biased responses with IgG1 predominance. Overall,
the co-infection of MHV-68 and NC viruses successfully switched
the NC-specific humoral response from a Th2 bias to a Th1 bias in
DR1 Tg mice. The mechanism behind this observation was still
unclear.
The dispersion of different isotypes of circulating NC-specific
Abs in sera also reflected the ASCs response. Isotype profiles were
similar after co-infection between DR1 Tg mice and B10 mice,
showing higher NC-specific IgG2c production than IgG1 (Fig. 12, AD). But neutralizing Abs titers were below the limit of measurement
in both groups. Since the NC-specific immune response was
changed by co-infection with MHV-68 virus compared with i.n. NC
infection, we wanted to know whether the virus replication in the
lung was also changed. By comparing virus titers between NC-only
infection and co-infection groups on day 8, no significant difference
was observed.
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Figure legend
Fig. 1 The primary influenza-specific ASCs response to intranasal
administration of NC in DR1 Tg mice and B10 mice. The kinetics of virusspecific ASC responses in the CLN (A), MLN (B), spleen (C), lung (D) and
BM (E) were determined in mice infected with NC intranasally. The
ELISPOT assay was used to enumerate virus-specific ASCs in single cell
suspensions from individual mouse. Results were expressed as the
number of ASCs/105 nucleated cells or the number of ASCs/5x105
nucleated cells. CLN, cervical lymph node; MLN, mediastinal lymph node;
BM, bone marrow. Data were mean + SE (n > 3).
Fig. 2 The influenza-specific Abs level in serum after intranasal
administration of NC in DR1 Tg mice and B10 mice. The kinetics of virusspecific Abs titers of different isotypes, IgG1 (A), IgG2b (B), IgG2c (C),
IgG3 (D), IgM (E), IgA (F), were measured by ELISA. Results were
determined by endpoint titration and did not necessarily reflect the relative
amount of each isotype. Data were mean + SE (n > 3).
Fig. 3 The influenza-specific immunoglobulin level and neutralizing Abs
titers and hemagglutination inhibition titers in serum after intranasal
administration of NC in DR1 Tg mice and B10 mice. (A) The kinetics of
virus-specific Ig was measured by ELISA and results were determined by
endpoint titration. (B) Neutralizing Abs titers in serum were measured by
neutralization assay. Results were expressed as the reciprocal of the
highest serum dilution completely preventing virus infection of MDCK cells.
(C) HAI titers in serum were measured by hemagglutination inhibition
assay and results were expressed as the reciprocal of the highest serum
dilution completely inhibiting hemagglutination activity of standardized
viruses.
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Fig. 4 Virus replication in the lung after intranasal infection of NC in DR1
Tg mice and B10 mice. Lungs of infected mice were collected at different
time intervals post-infection. Lung homogenates were used to perform
TCID50. Viral titers were determined by endpoint dilution that infected 50%
MDCK cells. Results were expressed as log10TCID50 / 0.2 ml lung
homogenates. Data were mean + SE (n > 3).
Fig. 5 Germinal center formation in the MLN of DR1 Tg mice and B10
mice after i.n. NC infection. Lymphocytes were isolated and analyzed on
days 8, 10, 14 and 21 after infection. (A) Flow cytometry of germinal
center B cells in the MLN. Gated B220+ B cells were shown. PNAhiFashi
germinal center B cells were boxed, with the percentage of B220+ B cells
indicated. (B) The number of germinal center B cells (B220+PNAhiFashi)
per MLN. (C-D) Frequencies of germinal center B cells expressed as the
number of B220+PNAhiFashi per 106 lymphocytes or 105 B220+ cells,
respectively. MLN, mediastinal lymph node. Data were mean + SE (n > 3).
Fig. 6 Comparison of influenza-specific and non-specific ASCs responses
in the MLN of DR1 Tg mice and B10 mice following intranasal infection of
NC. MLNs were collected from infected mice on days 10 (A) and 14 (B)
after infection. The ELISPOT assay was used to enumerate ASCs in
single cell suspensions from individual mouse. Purified NC viruses and
goat anti-mouse Abs were used to coat ELISPOT plates, respectively.
Results were expressed as the number of ASCs/105 nucleated cells. MLN,
mediastinal lymph node.
Fig. 7 The primary influenza-specific ASCs response to intramuscular
administration of inactivated NC in DR1 Tg mice and B10 mice. Mice were
sampled at days 8 and 10 after i.m vaccination with inactivated NC.
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IngLNs (A), IliLNs (B), and spleens (C) were collected on day 8 and PLNs
(D), IliLNs (E) and spleens (F) were collected on day 10. The ELISPOT
assay was used to enumerate virus-specific ASCs in single cell
suspensions from individual mouse. Results were expressed as the
number of ASCs/5x105 nucleated cells. IngLN, inguinal lymph node; IliLN,
iliac lymph node; PLN, popliteal lymph node. Data were mean + SE (n > 3).
Fig. 8 The influenza-specific ASCs response to intranasal administration
of influenza virus PR8 in DR1 Tg mice and B10 mice. MLNs of B10 mice
(A) and DR1 Tg mice (B) were collected and processed into single cell
suspensions on days 6, 8 and 10 after i.m. immunization. The ELISPOT
assay was used to enumerate PR8-specific ASCs from individual mouse.
Results were expressed as the number of ASC/105 nucleated cells. MLN,
mediastinal lymph node. Data were mean + SE (n > 3).
Fig. 9 Influenza-specific Abs levels in serum after intranasal infection of
PR8 in DR1 Tg mice and B10 mice. The kinetics of virus-specific Abs
titers of different isotypes, IgG1 (A), IgG2b (B), IgG2c (C), IgG3 (D), IgM
(E), and IgA (F), were determined by ELISA. Results were determined by
endpoint titration and did not necessarily reflect the relative amount of
each isotype. Data were mean + SE (n > 3).
Fig. 10 Neutralizing Abs titers in serum and viral growth in the lung after
intranasal infection of PR8 in DR1 Tg mice and B10 mice. (A) Neutralizing
Abs titers in serum were determined by neutralization assay. Results were
expressed as the reciprocal of the highest dilution of the serum completely
preventing virus infection of MDCK cells. (B) Lung homogenates of
infected mice were used to perform TCID50 to measure the virus growth in
lungs. Viral titers were determined by endpoint dilution that infected 50%
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MDCK cells. Results were expressed as log10TCID50 /0.2 ml lung
homogenates.
Fig. 11 Influenza-specific ASCs responses in mice co-infected with NC
and MHV-68 viruses. DR1 Tg mice and B10 mice were intranasally
infected by NC and MHV-68 viruses. MLNs were collected on days 8 (A-B)
and 10 (C-D) post-infection. The ELISPOT assay was used to enumerate
virus-specific ASCs from individual mouse. Purified NC viruses and
purified MHV-68 viruses were used to coat ELISPOT plates to measure
NC-specific ASCs (A, C) and MHV-68-specific ASCs (B, D), respectively.
Results were expressed as the number of ASCs/105 nucleated cells. MLN,
mediastinal lymph node.
Fig. 12 Influenza-specific Abs levels in serum of mice co-infected with NC
and MHV-68 viruses. Titers of different NC-specific isotypes (A-D) and
NC-specific immunoglobulin (E) were determined by ELISA. Results were
determined by endpoint titration and did not necessarily reflect the relative
amount of each isotype. (F) Comparison of viral titers in lungs between
NC-only and co-infected mice on day 8. Virus titers were determined by
endpoint dilution that infected 50% MDCK cells. Results were expressed
as log10TCID50 / 0.2 ml lung homogenates.

38

CHAPTER 4
DISCUSSION
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The transgenic mouse model system used in this study contains a
human MHC class II molecule HLA-DR1 [80-82] and provides a useful
model for evaluating the diversity and specificity of CD4 T cell responses
that may develop in humans following influenza virus infection or
vaccination [77, 83]. The influenza virus A/New Caledonia/20/99 (NC)
used in the study is not a mouse-adapted isolate and has been circulating
in the North American human populations for more than 10 years [84]. The
influenza-specific B cell response to intranasal administration (i.n.) of NC
was analyzed in HLA-DR1 transgenic mice (DR1 Tg) and in the
genetically matched H-2b strain C57BL/10J (B10). The B cell ELISPOT
assay was used to characterize the production of virus-specific ASCs at
the single cell level. In B10 mice, the B cell response in draining LNs was
typical of previously described B cell responses to a variety of mouseadapted influenza viruses, characterized by a Th1 bias, as indicated by a
stronger IgG2c production. In contrast, the B cell response in DR1 Tg
mice followed delayed kinetics and was strongly skewed to a Th2 bias, as
indicated by a stronger IgG1 production. This phenomenon was observed
in draining LNs and spleens. Another interesting feature of the B cell
response to NC infection in DR1 Tg mice was that there were higher
neutralizing Abs titers and hemagglutination inhibition (HAI) titers on day
14 after virus infection compared with B10 mice.
However, the IgG1/Th2 bias was not a characteristic of all B cell
responses in DR1 Tg mice. After intramuscular vaccination of inactivated
NC, the virus-specific B cell response displayed a strong IgG2c/Th1 bias
instead of the IgG1 skewing in draining LNs and spleens. This feature was
also evident when PR8 (H1N1 isolate) was given intranasally. The PR8specific B cell response after intranasal infection demonstrated a totally
different isotype profile, demonstrating a massive PR8-specific IgM/IgG3
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production. The virus-specific IgG1 skewing which was evident after i.n.
NC infection in DR1 Tg mice was also abolished. Based on these
observations, we concluded that the unusual IgG1/Th2 bias was restricted
to the intranasal infection of NC in DR1 Tg mice.
Additional experiments were conducted to probe the mechanism
behind the NC-specific IgG1/Th2 bias in DR1 Tg mice. Murine
gammaherpesvirus 68 (MHV-68) is a member of the γ-herpesvirus family,
that infects epithelial cells and mononuclear cells in the lower respiratory
tract [85]. A previous study showed that MHV-68-specific B cell responses
after i.n. infection were characterized by a predominant IgG2a/IgG2b
ASCs production and a low level of IgG1 production [79]. Therefore, we
speculated that the Th2 biased B cell response in DR1 Tg mice following
i.n. NC infection could be altered by a co-infection with MHV-68, which is a
Th1 biased virus. Our data demonstrated that in co-infected DR1 Tg mice,
the IgG1 biased NC-specific B cell response in draining LNs was
abolished. Instead, the isotype profile skewed towards the IgG2c/Th1 bias.
Notably, the MHV-68-specific response did not change as a result of the
co-infection. The mechanism underlying this observation was still not clear.
The current study raised several questions, such as what factors
drove the antibody isotype switching to IgG1 in DR1 Tg mice after i.n. NC
infection, and why the neutralizing Abs titer and the HAI titer were higher
although the titer of virus-specific immunoglobulin in serum was lower in
DR1 Tg mice compared to B10 mice. The B cell activation is dependent
on help signals received from CD4 T cells, and the priming of CD4 T cells
relies on antigen presentations by professional APCs, especially infected
dendritic cells (DCs) [86-88]. We speculated that the antigen presentation
process after influenza virus infection contributed to these observations in
DR1 Tg mice. The high level synthesis of viral proteins within infected DCs
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could override some factors that usually restrict the presentation of
endogenous peptides by MHC class II molecules, resulting in broader
diversity of CD4 T cell specific repertoire [77]. Also higher numbers of
antigen-bearing DCs in lymph nodes after influenza virus infection can
help diversify the CD4 T cell specific repertoire by reducing the
competition for antigens [89]. After intranasal infection, NC can replicate
better in infected epithelial cells and DCs; but after intramuscular
vaccination, NC lose the access to replicate in these cells. Therefore,
antigen presentations by DCs after i.n. and i.m. could be quite different,
resulting in distinct CD4 T cells priming and the down-stream B cell
activation. In vitro studies have indicated that the up-regulated expression
of MHC class II molecules and co-stimulatory molecules, like CD40 and
OX40L, on activated DCs mediated Th2 differentiation [90, 91]. Current
studies focusing on the CD4 T cell specific repertoire after NC virus
infection showed a much broader distribution of CD4 T cells specific
epitopes in DR1 Tg mice, while previous studies identified restricted CD4
T cell specific repertoire in C57BL/6 mice [75, 77, 83]. The CD4 T cell
specific repertoire in B10 after NC primary infection was revealed to be
narrow and was limited to certain proteins.
Besides different diversities of the CD4 T cell repertoire between
DR1 Tg mice and B10 mice, different specificities of CD4 T cells may also
play an important role in the immune response. One hypothesis underlying
the current project is that B cells display a limited subset of influenzaderived peptides specificities that are mainly restricted to antigens from
HA, NA and M2. The specificity of CD4 T cells that help Ag-specific B cells
to produce neutralizing antibodies in vivo after influenza infection is largely
restricted to these peptides derived from HA, NA and M2, especially the
HA [83]. The remaining CD4 T cells with specificities for internal viral
antigens may be counterproductive to the protective immunity by
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occupying needed “space” in the CD4 T cell memory compartment [83]. T
cells and B cells with the same specificity can form long-lasting cognate
interactions which ensure B cells get essential and enough help signals to
undergo further differentiation, immunoglobulin isotype switching and
affinity maturation [92, 93]. Studies done by our collaborating lab at the
University of Rochester (Andrea Sant’s lab) demonstrated that the
repertoire of HA-specific CD4 T cells after primary influenza infection in
DR1 Tg mice was very broad, containing more than 30 different
specificities within the entire HA [77]. However, in B10 mice, the majority
of CD4 T cell-specific epitopes were derived from NP and NA [94].
Therefore, the diverse HA-specific CD4 T cells in DR1 Tg mice would be
more effective in activating HA-specific B cells and facilitating the
neutralizing Abs production. On the other hand, in B10 mice, NP-specific
CD4 T cells would weaken the HA-specific B cell activation and the
neutralizing Abs production.
Help signals from activated CD4 T cells to B cells and CD8 T cells
are mainly mediated by different cytokines. Cytokines from Th1 cells, like
IL-2 and IFN-γ, can activate CD8 T cells and facilitate isotype switching to
IgG2a/IgG2c; cytokines from Th2 cells, such as IL-4 and IL-5, mainly
provide help for B cells activation and help IgA, IgE, and IgG1 production
[34]. Therefore, we speculated that different cytokines profiles induced by
i.n. NC infection might contribute to the IgG1/Th2 bias observed in DR1 Tg
mice. Results from Andrea’s lab showed that similar levels of IL-4, IL-2
and IFN-γ were present in DR1 Tg mice after i.n. NC infection, while very
minimal IL-4 was detected in B10 mice (data not shown). The Th2 type
cytokine IL-4 in DR1 Tg mice quite possibly contributed to the IgG1/Th2
bias, while the predominance of Th1 type cytokines in B10 mice enabled
the B cell response to polarize towards a Th1 bias. In addition, Th1 type
cytokines in B10 mice would effectively activate CD8 T cells, which might
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explain the rapid virus clearance observed in B10 mice after i.n. NC
infection. In the co-infection experiment, the production of IFN-γ and IL-6
induced by MHV-68 infection might contribute to the isotype switching to
IgG2c in DR1 Tg mice.
In this study we also compared the virus-specific and non-specific B
cell activation after NC infection between DR1 Tg mice and B10 mice. In
B10 mice, the virus-specific B cell response in the MLN was accompanied
by a strong non-specific ASCs production on days 8 and 10, displaying
IgG2c predominance. Since the immune response was delayed during the
early phase after NC infection in DR1 Tg mice, both the virus-specific and
non-specific responses were weak on day 8. The increase of non-specific
ASCs was not significant on days 10 and 14, except the non-specific IgG1
ASCs. Research showed that strong and even normal virus-specific CD4
T cell activation resulted in an increased early polyclonal B cell activation,
which competed with the virus-specific B cell activation and the formation
of neutralizing Abs [78]. Polyclonal B cell activation was reflected by nonspecific antibodies production and required the involvement of activated B
cells in germinal center processes [79]. We speculated that the strong
early non-specific B cell activation in B10 mice inhibited the virus-specific
B cell activation and maybe responsible for the lower neutralizing Abs titer.
But it was still unclear about the source and the function of the massive
non-specific IgG1 ASCs in DR1 Tg mice.
Since the germinal center (GC) is the main place supporting the
somatic hypermutation, the affinity maturation, and the formation of
memory B cells [68], we compared the GC reaction in MLNs after i.n. NC
infection between DR1 Tg mice and B10 mice by staining lymphocytes
with GC markers peanut agglutinin (PNA) and Fas (also known as CD95)
[95, 96]. We calculated the total number of GC B cells per lymph node and
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found no difference between two groups. We also calculated the GC B cell
frequency per 106 lymphocytes, and there was no difference, except on
day 21 after infection. However, there are alternative ways to examine the
GC B cell response by using different GC markers combinations, such as
B220+PNAhi,

B220+Gl7hi,

B220+IgDloFashiPNAhiCD38int,

or

B220+PNAhiGl7hiFashi [95-98]. When we compared the percent of
B220+PNAhi population, there seemed to be a higher percentage of these
cells in DR1 Tg mice than B10 mice. At this stage, the GC reaction has
not been fully characterized in DR1 Tg mice and B10 mice, and it is still
largely unclear whether the GC reaction is related to different immune
response patterns. More experiments are needed in this direction in order
to clarify this issue.
In addition to GC B cells, there are two other important cell types that
are also involved in the GC reaction, follicular DCs and follicular helper T
cells [96, 99]. Both of them play crucial roles in the BCRs affinity selection
in the GC. Follicular helper T cells are a subset of activated CD4 T cells
and are characterized by high expression of CXCR5 and co-stimulatory
molecules CD40L and ICOS [70]. Follicular helper T cells can secrete high
level of IL-4 and shape the B cell response, especially the IgG1 isotype
switching and affinity maturation [96]. It will be interesting to perform
experiments that will compare follicular helper T cells frequencies between
DR1 Tg mice and B10 mice. Understanding the mechanism underlying the
unusual IgG1/Th2 bias in DR1 Tg mice after i.n. NC infection can provide
useful insights into the regulation of immunoglobulin isotypes expression
in DR1 Tg mice.
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Figure 1. The primary influenza-specific ASCs response to intranasal
administration of NC in DR1 Tg mice and B10 mice
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Figure 2. The influenza-specific Abs level in serum after intranasal
administration of NC in DR1 Tg mice and B10 mice
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Figure 5. Germinal center formation in the MLN of DR1 Tg mice and B10
mice after i.n. NC infection
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Figure 11. Influenza-specific ASCs responses in mice co-infected
with NC and MHV-68 viruses

68

B10 IgGs coinfection

Dilution (reciprocal)

10 5

B10

IgG1
IgG2b
IgG2c
IgG3

10 4

DR1 Tg IgGs coinfection

C

10 5

Dilution (reciprocal)

A

10 3

10 2

DR1 Tg
IgG1
IgG2b
IgG2c
IgG3

10 4

10 3

10 2
8

10

8

Days P.I.

Days P.I.

B10 IgM and IgA coinfection

Dilution (reciprocal)

10 5

B10

DR1 Tg IgM and IgA coinfection

D

IgM
IgA

10 5

Dilution (reciprocal)

B

10 4

10 3

8

DR1 Tg

10 3

10 2

10

8

10

Days P.I.

Days P.I.

Total Ig coinfection
virus-specific
Ig
B10
DR1 Tg

10 5

virus titer in lung

F

8

TCID50 ( Log10/0.2 ml )

Dilution (reciprocal)

10 6

10 4
10 3
10 2
8

IgM
IgA

10 4

10 2

E

10

DR1 Tg

4
2
0

10

B10

6

NC only

coinfection

Days P.I.

Figure 12. Influenza-specific Abs levels in serum of mice co-infected with
NC and MHV-68 viruses
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